Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
4.920
-0.030 (-0.61%)
Apr 24, 2025, 4:00 PM EDT - Market closed

Company Description

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.

Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is in phase 2 clinical trial to treat inflammatory diseases.

The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021.

Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Avalo Therapeutics, Inc.
Avalo Therapeutics logo
Country United States
Founded 2011
IPO Date Oct 15, 2015
Industry Biotechnology
Sector Healthcare
Employees 23
CEO Garry Neil

Contact Details

Address:
540 Gaither Road, Suite 400
Rockville, Maryland 20850
United States
Phone 410 522 8707
Website avalotx.com

Stock Details

Ticker Symbol AVTX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001534120
CUSIP Number 05338F108
ISIN Number US05338F3064
Employer ID 45-0705648
SIC Code 2834

Key Executives

Name Position
Dr. Garry A. Neil M.D. President, Chief Executive Officer and Director
Christopher Ryan Sullivan CPA Chief Financial Officer and Head of Investor relations
Dr. Mittie Doyle FACR, M.D. Chief Medical Officer
Dr. Solomon H. Snyder M.D. Founder and Chairman of Scientific Advisory Board
Dr. Barbara S. Slusher Ph.D. Founder and Member of Scientific Advisory Board
Paul C. Varki J.D., M.P.H Chief Legal Officer
Dr. Lisa Hegg Ph.D. Senior Vice President of Program Management, Business Development and Corporate Infrastructure
Colleen Matkowski Senior Vice President of Global Regulatory Affairs and Quality Assurance
Dr. Dino C. Miano Ph.D. Senior Vice President of CMC and Technical Operations
Jennifer Riley Chief Strategy Officer

Latest SEC Filings

Date Type Title
Mar 26, 2025 8-K Current Report
Mar 20, 2025 10-K Annual Report
Mar 20, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Jan 13, 2025 8-K Current Report
Jan 2, 2025 8-K Current Report
Dec 31, 2024 SCHEDULE 13G Filing
Dec 5, 2024 8-K Current Report
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals